Osong, South Korea, March 20th, 2020
Naason Science sends out its hopes that everyone takes all of the prescribed precautions and stays as safe as possible at this time. Nevertheless, we would also like to assure all of our local and global collaborators that we are not experiencing any disruption in business at this time. In many ways, the Korean people and the Korean health authorities have worked admirably to cope with the outbreak of COVID-19, and this has resulted in no disruptions in Naason Science´s ability to maintain its study schedules.
We remain vigilant and carry out all precautions in order to protect ourselves, our co-workers as well as our families and fellow citizens while, at the same time, we stay mindful of the fact that the work that we carry out in conjunction with our collaborators and our partners is of the ultimate importance to their aspirations. In the event that there would be a change in our current situation, we will contact all of our collaborators, clients and partners immediately and directly.
Since many of our ongoing projects have an effect on the health and wellbeing of people, we remain committed to all of the work that we are performing and, in fact, have ramped up our capabilities to accommodate additional investigations.
For additional information please contact firstname.lastname@example.org
Naason Science CEO Larry Park was interviewed to 7CJB News during visit of President Moon to KBio New Drug Development Center .
Larry´s comments at 1:30 min.
English subtitles coming soon!
August 10, 2019 - Naason Science has recently completed validation of the models within it’s Orthopedic modelling platform. These models include models for primary and secondary (post-traumatic, congenital etc.) OA. All models can combine MRI and CT micro-CT. The models are available in a variety of species.
The models are:
▪ Surgical model for ACLT
▪ Surgical model for Meniscectomy (MMT)
▪ Collagenase Injection
▪ Sodium monoiodoacetate /MIA
▪ Crystallin alpha B KO mouse model
The models can incorporate histopathology and biochemical analysis as we all as imaging as well as 24/7 home-cage monitoring for:
▪ General locomotion
▪ Circadian Rythm
▪ Anticipatory behaviour
▪ Social distancing – anxiety & depression
▪ Climbing/rearing behaviour
▪ Gait Analysis
For more information about our Modelling Platform for Osteoarthritis please contact email@example.com.
Copyright Naason Science
Osong, South Korea, July 10, 2019 - Addex Therapeutics announced July 9 that it will lead a consortium for the development of small-molecule negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 7 (mGlu7) as a potential treatment to reduce fear memory in post-traumatic stress disorder (PTSD). The project, named DiSARM FEAR, has been awarded a €4.85 million Eurostars grant to cover research activities performed by all participants, including Naason Science (South Korea), Endotherm (Germany), Nucro Technics (Canada) and Radboud University (Netherlands), in addition to Addex.
PTSD is a serious anxiety disorder that can lead to intense fear and anxiety. Current medication is unspecific and ineffective, with a number of side effects. By selectively targeting mGlu7 with NAMs, the brain circuitries involved in fear and anxiety can be precisely modulated, potentially resulting in higher efficacy and fewer side effects.
The project will capitalize on the significant discovery and preclinical investigations already achieved at Addex, including preclinical studies performed using ADX71743, a prototypical selective mGlu7 receptor NAM identified and characterized by Addex (Kalinichev et al. 2013. J.Pharmcol.Exp. Ther. 344, 624-636). Published and unpublished data generated with this compound in preclinical models demonstrates the central role of mGlu7 receptors in key processes involved in fear memory. The DiSARM FEAR project aims to generate novel mGlu7 NAMs ready to enter IND enabling studies within 3 years.
Naason Science’s CSO Jonathan Friedman said of the project, “Naason’s inclusion within the consortium confirms the expertise and acumen we have been building in the area of modelling neurological and psychiatric disorders over the last few years. We are delighted to be able to collaborate with Addex and the other consortium members to quickly and effectively complete the preclinical work and facilitate the IND enabled studies in an area where there is a significant global unmet clinical need”.
“This important research not only advances a potential new avenue in PTSD but could provide insight to other neurological disorders,” said Tim Dyer, CEO of Addex. “This project is another example of our strategy to leverage non-dilutive funding and a collaborative approach to maximize the value of our unique allosteric modulation discovery platform technology, potentially leading to multiple new products for our pipeline.”
About Naason Science: Naason Science is a global leader in contract and collaborative research aimed at preclinical drug development in a variety of therapeutic areas. Naason´s various preclinical modelling platforms are customized to suit the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a toolbox of state-of-the-art technologies that allow for rapid and effective testing of preclinical drug candidates.
Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
May 20, 2019 - Naason Science is now offering Efficacy Evaluation of Compounds in a Rat Model of Dry Eye Disease. The objective of the model to investigate whether the compound has an anti-dry eye syndrome effect in a Rat Model of Dry Eye Disease induced by Extraorbital Lacrimal Gland Excision (ELGE).
In our pilot study ELGE surgery was performed after the body weight was measured on day 1. The test substance was administered in eyeballs and treatments were continued for 14 days after 1 week of ELGE surgery. The Schirmer test on the rats’ both left and right eyes were carried out to measure basal and reflective tear secretion. The efficacious effects of compounds were compared also to Xiidra® (Shire US Inc, USA) as FDA approved eye drop syndrome agent.
For more information about our Rat Model for Dry Eye Disease please contact firstname.lastname@example.org.